US7528239B1
(en)
|
1997-02-13 |
2009-05-05 |
Immunex Corporation |
Receptor that binds trail
|
US6072047A
(en)
*
|
1997-02-13 |
2000-06-06 |
Immunex Corporation |
Receptor that binds trail
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
US20040136951A1
(en)
*
|
1997-03-17 |
2004-07-15 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
EP1788086A1
(de)
*
|
1997-03-17 |
2007-05-23 |
Human Genome Sciences, Inc. |
Rezeptor 5, der eine für den Zelltod verantwortliche Domäne enthält
|
US6872568B1
(en)
*
|
1997-03-17 |
2005-03-29 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5 antibodies
|
CN1624128A
(zh)
|
1997-03-17 |
2005-06-08 |
人类基因组科学公司 |
包含死亡结构域的受体-5
|
US20050233958A1
(en)
*
|
1997-03-17 |
2005-10-20 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US20080248046A1
(en)
*
|
1997-03-17 |
2008-10-09 |
Human Genome Sciences, Inc. |
Death domain containing receptor 5
|
US6342369B1
(en)
*
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
US20100152426A1
(en)
*
|
1997-05-15 |
2010-06-17 |
Ashkenazi Avi J |
Apo-2 receptor fusion proteins
|
AU9376498A
(en)
*
|
1997-09-05 |
1999-03-22 |
University Of Washington |
Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
|
JP2002517223A
(ja)
*
|
1998-06-12 |
2002-06-18 |
ジェネンテック・インコーポレーテッド |
モノクローナル抗体、交叉反応性抗体およびそれを生成する方法
|
DE60042066D1
(de)
*
|
1999-05-28 |
2009-06-04 |
Genentech Inc |
Chimärische dr4 antikörper und ihre verwendung
|
ZA200002867B
(en)
*
|
1999-06-09 |
2001-12-07 |
Pfizer Prod Inc |
Process for preparing sertraline from chiral tetralone.
|
WO2001000832A1
(en)
|
1999-06-28 |
2001-01-04 |
Genentech, Inc. |
Methods for making apo-2 ligand using divalent metal ions
|
CA2384762A1
(en)
*
|
1999-09-15 |
2001-03-22 |
Genentech, Inc. |
Apo-2 receptor antibodies
|
WO2001058954A2
(en)
*
|
2000-02-11 |
2001-08-16 |
Genetics Institute, Llc. |
Trade molecules and uses related thereto
|
IL150755A0
(en)
|
2000-02-16 |
2003-02-12 |
Genentech Inc |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
CN100390288C
(zh)
|
2000-04-11 |
2008-05-28 |
杰南技术公司 |
多价抗体及其应用
|
US7279160B2
(en)
|
2000-05-02 |
2007-10-09 |
The Uab Research Foundation |
Combinations of DR5 antibodies and other therapeutic agents
|
TWI318983B
(en)
|
2000-05-02 |
2010-01-01 |
Uab Research Foundation |
An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
|
US7476383B2
(en)
|
2000-05-02 |
2009-01-13 |
The Uab Research Foundation |
Antibody selective for DR4 and uses thereof
|
ATE415978T1
(de)
|
2000-07-27 |
2008-12-15 |
Genentech Inc |
Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
|
US20060062786A1
(en)
*
|
2000-11-08 |
2006-03-23 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
US20030228309A1
(en)
*
|
2000-11-08 |
2003-12-11 |
Theodora Salcedo |
Antibodies that immunospecifically bind to TRAIL receptors
|
US7115717B2
(en)
|
2001-05-18 |
2006-10-03 |
Kirin Beer Kabushiki Kaisha |
Anti-TRAIL-R antibodies
|
US20050214209A1
(en)
*
|
2001-05-25 |
2005-09-29 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
US20050129616A1
(en)
*
|
2001-05-25 |
2005-06-16 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
KR100942393B1
(ko)
*
|
2001-05-25 |
2010-02-17 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
Trail 수용체에 면역특이적으로 결합하는 항체
|
US7361341B2
(en)
*
|
2001-05-25 |
2008-04-22 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
|
US20090226429A1
(en)
*
|
2001-05-25 |
2009-09-10 |
Human Genome Sciences, Inc. |
Antibodies That Immunospecifically Bind to TRAIL Receptors
|
US7348003B2
(en)
|
2001-05-25 |
2008-03-25 |
Human Genome Sciences, Inc. |
Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
|
JP4509570B2
(ja)
|
2001-07-03 |
2010-07-21 |
ジェネンテック, インコーポレイテッド |
ヒトdr4抗体及びその使用法
|
US20040186051A1
(en)
|
2001-10-02 |
2004-09-23 |
Kelley Robert F |
Apo-2 ligand variants and uses thereof
|
PT1450847E
(pt)
|
2001-11-13 |
2011-01-05 |
Genentech Inc |
Formulações de ligando de apo2/trail e suas utilizações
|
US7741285B2
(en)
|
2001-11-13 |
2010-06-22 |
Genentech, Inc. |
APO-2 ligand/trail formulations
|
US7842668B1
(en)
|
2001-11-13 |
2010-11-30 |
Genentech, Inc. |
Apo-2 ligand/trail formulations
|
US20030180296A1
(en)
*
|
2001-12-20 |
2003-09-25 |
Theodora Salcedo |
Antibodies that immunospecifically bind to trail receptors
|
JP4460302B2
(ja)
|
2002-02-05 |
2010-05-12 |
ジェネンテック インコーポレイテッド |
タンパク質精製法
|
PT1501369E
(pt)
|
2002-04-26 |
2015-09-21 |
Genentech Inc |
Purificação de proteínas com base na não afinidade
|
US20060141561A1
(en)
|
2002-06-24 |
2006-06-29 |
Kelley Robert F |
Apo-2 ligand/trail variants and uses thereof
|
WO2004003144A2
(en)
|
2002-07-01 |
2004-01-08 |
Human Genome Sciences, Inc. |
Antibodies that specifically bind to reg iv
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
KR20160114727A
(ko)
|
2003-05-30 |
2016-10-05 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
AU2004265253B2
(en)
|
2003-07-28 |
2011-09-01 |
Genentech, Inc. |
Reducing protein A leaching during protein A affinity chromatography
|
EP1531162A1
(de)
*
|
2003-11-14 |
2005-05-18 |
Heinz Vollmers |
Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen
|
JP2007530588A
(ja)
|
2004-03-23 |
2007-11-01 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
レセプターカップリング剤およびその治療用途
|
KR101235479B1
(ko)
|
2004-08-06 |
2013-02-20 |
제넨테크, 인크. |
바이오마커를 사용한 분석 및 방법
|
EP1778871B1
(de)
|
2004-08-06 |
2011-05-04 |
Genentech, Inc. |
Tests und verfahren unter verwendung von biomarkern
|
US7662926B2
(en)
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
US7655229B2
(en)
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
ZA200706246B
(en)
*
|
2005-02-02 |
2008-11-26 |
Genentech Inc |
DR5 antibodies and uses thereof
|
US8029783B2
(en)
*
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
BRPI0606791A2
(pt)
|
2005-02-02 |
2010-02-09 |
Uab Research Foundation |
métodos de reverter ou prevenir a resistência de uma célula a um agonista do receptor da morte, de triar uma célula quanto a um biomarcador da resistência a um agonista do receptor da morte, de monitorar a resistência a um agonista do receptor da morte em um indivìduo, de induzir seletivamente a apoptose em uma célula alvo expressando um receptor da morte, de tratar de um indivìduo com cáncer, de tratar de um indivìduo com uma doença inflamatória ou autoimune, de bloquear a ligação da proteìna contendo card a um receptor da morte em uma célula, de bloquear a associação de um iap com o receptor da morte e de triar um modulador de uma proteìna contendo card, composição, ácido nucleico isolado, vetor, célula, e, polipeptìdeo isolado
|
US20060188498A1
(en)
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
ZA200800974B
(en)
|
2005-08-16 |
2009-11-25 |
Genentech Inc |
Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues
|
PE20071101A1
(es)
*
|
2005-08-31 |
2007-12-21 |
Amgen Inc |
Polipeptidos y anticuerpos
|
EP1952150B1
(de)
|
2005-11-23 |
2016-12-14 |
Genentech, Inc. |
Verfahren und zusammensetzungen in verbindung mit b-zellen-testverfahren
|
KR20080090408A
(ko)
|
2005-11-30 |
2008-10-08 |
아보트 러보러터리즈 |
항-Aβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
|
KR101439828B1
(ko)
|
2005-11-30 |
2014-09-17 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
|
ES2388932T3
(es)
|
2005-12-02 |
2012-10-19 |
Genentech, Inc. |
Polipéptidos de unión y usos de los mismos
|
FR2902799B1
(fr)
|
2006-06-27 |
2012-10-26 |
Millipore Corp |
Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8362217B2
(en)
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
US20100267933A1
(en)
|
2006-12-21 |
2010-10-21 |
Moya Wilson |
Purification of proteins
|
ZA200904482B
(en)
|
2007-01-22 |
2010-09-29 |
Genentech Inc |
Polyelectrolyte precipitation and purification of antibodies
|
US8895004B2
(en)
|
2007-02-27 |
2014-11-25 |
AbbVie Deutschland GmbH & Co. KG |
Method for the treatment of amyloidoses
|
MX354993B
(es)
|
2007-07-09 |
2018-03-28 |
Genentech Inc |
Prevención de reducción de enlaces de disulfuro durante la producción recombinante de polipéptidos.
|
KR20150008503A
(ko)
|
2007-10-30 |
2015-01-22 |
제넨테크, 인크. |
양이온 교환 크로마토그래피에 의한 항체 정제
|
WO2009151514A1
(en)
|
2008-06-11 |
2009-12-17 |
Millipore Corporation |
Stirred tank bioreactor
|
JP5666447B2
(ja)
|
2008-08-14 |
2015-02-12 |
ジェネンテック, インコーポレイテッド |
常在性タンパク質置換イオン交換メンブレンクロマトグラフィを用いた混入物除去方法
|
US20100068210A1
(en)
|
2008-09-10 |
2010-03-18 |
Ji Junyan A |
Compositions and methods for the prevention of oxidative degradation of proteins
|
EP2379585A2
(de)
|
2008-10-10 |
2011-10-26 |
Anaphore, Inc. |
Trail-r1 und trail-r2 bindende polypeptide
|
US20110020327A1
(en)
|
2008-12-16 |
2011-01-27 |
Millipore Corporation |
Purification of proteins
|
ES2749232T3
(es)
|
2008-12-16 |
2020-03-19 |
Emd Millipore Corp |
Reactor de tanque agitado y procedimiento
|
CA2752884A1
(en)
|
2009-02-27 |
2010-09-02 |
Genentech, Inc. |
Methods and compositions for protein labelling
|
KR20200111282A
(ko)
|
2009-08-11 |
2020-09-28 |
제넨테크, 인크. |
글루타민-비함유 세포 배양 배지에서의 단백질의 생성
|
PL2473617T3
(pl)
|
2009-09-01 |
2020-06-29 |
F. Hoffmann-La Roche Ag |
Ulepszone oczyszczanie białka poprzez zmodyfikowaną elucję z białka A
|
US9238069B2
(en)
|
2009-12-16 |
2016-01-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
|
NZ602368A
(en)
|
2010-02-12 |
2014-10-31 |
Pharmascience Inc |
Iap bir domain binding compounds
|
ES2602971T3
(es)
|
2010-03-02 |
2017-02-23 |
Kyowa Hakko Kirin Co., Ltd. |
Composición de anticuerpo modificado
|
SI2550018T1
(sl)
|
2010-03-22 |
2019-05-31 |
F. Hoffmann-La Roche Ag |
Sestavki in metode, uporabni za stabilizacijo formulacij, ki vsebujejo beljakovine
|
WO2011118739A1
(ja)
|
2010-03-26 |
2011-09-29 |
協和発酵キリン株式会社 |
新規修飾部位導入抗体および抗体フラグメント
|
WO2011130377A2
(en)
|
2010-04-15 |
2011-10-20 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
RU2012151500A
(ru)
|
2010-05-03 |
2014-06-10 |
Дженентек, Инк. |
Композиции и способы, пригодные для снижения вязкости белковосодержащих составов
|
KR101827855B1
(ko)
|
2010-05-17 |
2018-02-12 |
이엠디 밀리포어 코포레이션 |
생체분자 정제용 자극 반응성 중합체
|
KR101869987B1
(ko)
|
2010-05-28 |
2018-07-20 |
제넨테크, 인크. |
락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
|
CA2802756C
(en)
|
2010-06-24 |
2021-05-04 |
Genentech, Inc. |
Compositions and methods for stabilizing protein-containing formulations
|
EP2610338A4
(de)
|
2010-08-02 |
2015-03-25 |
Kyowa Hakko Kirin Co Ltd |
Verfahren zur herstellung einer substanz
|
MX2013001267A
(es)
|
2010-08-13 |
2013-04-10 |
Genentech Inc |
ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
|
CN103298833B
(zh)
|
2010-08-14 |
2015-12-16 |
Abbvie公司 |
β淀粉样蛋白结合蛋白
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
SG189456A1
(en)
|
2010-10-29 |
2013-05-31 |
Daiichi Sankyo Co Ltd |
Novel anti-dr5 antibody
|
BR112013014949B1
(pt)
|
2010-12-15 |
2021-12-28 |
Inter-University Research Institute Corporation Research Organization Of Information And Systems |
Métodos para a produção de uma proteína de interesse e para a obtenção de uma suspensão de células cho capaz de sobreviver e proliferar em um meio sem soro que produz uma proteína de interesse
|
ES2812923T3
(es)
|
2010-12-27 |
2021-03-18 |
Kyowa Kirin Co Ltd |
Método para preparar una disolución acuosa que contiene medio de cultivo y agente quelante
|
WO2012117336A2
(en)
|
2011-02-28 |
2012-09-07 |
Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Per La Salute Della Donna E Del Bambino |
Apoptosis-inducing molecules and uses therefor
|
CA2834776A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
|
KR102038336B1
(ko)
|
2011-07-08 |
2019-10-31 |
이엠디 밀리포어 코포레이션 |
일회용 생명공학적 공정용의 개선된 심층 필터
|
ES2697676T3
(es)
|
2011-12-22 |
2019-01-25 |
Hoffmann La Roche |
Cromatografía de membrana de intercambio iónico
|
CN109880867A
(zh)
|
2012-03-27 |
2019-06-14 |
弗·哈夫曼-拉罗切有限公司 |
用于重组蛋白质的改进的收获操作
|
AU2013262611B2
(en)
|
2012-05-18 |
2018-03-01 |
Genentech, Inc. |
High-concentration monoclonal antibody formulations
|
EP2934602B1
(de)
|
2012-12-19 |
2019-02-27 |
Genentech, Inc. |
Verfahren und zusammensetzungen zur radiohalogen proteinmarkierung
|
PL2970473T3
(pl)
|
2013-03-14 |
2018-01-31 |
Bristol Myers Squibb Co |
Kombinacja agonisty dr5 i antagonisty anty-pd-1 oraz metody stosowania
|
CA2953154C
(en)
|
2014-07-09 |
2023-03-14 |
Genentech, Inc. |
Ph adjustment to improve thaw recovery of cell banks
|
WO2017139485A1
(en)
|
2016-02-09 |
2017-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
|
SG11201808562SA
(en)
|
2016-03-29 |
2018-10-30 |
Geltor Inc |
Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1
|
EP3323428A1
(de)
|
2016-11-17 |
2018-05-23 |
CNRS Centre National de la Recherche Scientifique |
Selektive c-flip-hemmer als antikrebsmittel
|
CA3044686A1
(en)
|
2016-12-22 |
2018-06-28 |
Genentech, Inc. |
Methods and formulations for reducing reconstitution time of lyophilized polypeptides
|
US11180541B2
(en)
|
2017-09-28 |
2021-11-23 |
Geltor, Inc. |
Recombinant collagen and elastin molecules and uses thereof
|
WO2019173499A1
(en)
|
2018-03-06 |
2019-09-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
17-beta-hydroxywithanolides and use thereof in treating cancer
|
EP3818078B1
(de)
|
2018-07-03 |
2024-02-28 |
Bristol-Myers Squibb Company |
Verfahren zur herstellung rekombinanter proteine
|
WO2020076776A1
(en)
|
2018-10-10 |
2020-04-16 |
Boehringer Ingelheim International Gmbh |
Method for membrane gas transfer in high density bioreactor culture
|
EP3875595A4
(de)
|
2018-11-02 |
2022-07-13 |
Kyowa Kirin Co., Ltd. |
Verfahren zur herstellung eines flüssigen mediums
|
WO2020205716A1
(en)
|
2019-04-01 |
2020-10-08 |
Genentech, Inc. |
Compositions and methods for stabilizing protein-containing formulations
|
TW202104254A
(zh)
|
2019-04-12 |
2021-02-01 |
美商格爾托公司 |
重組彈性蛋白及其生產
|
EP4007808A1
(de)
|
2019-08-01 |
2022-06-08 |
Bristol-Myers Squibb Company |
Verfahren zur verbesserung der proteinproduktivität in fed-batch-zellkulturen
|
MX2022006670A
(es)
|
2019-12-03 |
2023-03-17 |
Shanghai Jiao Tong Univ School Of Medicine |
Region fc de anticuerpo teniendo mayor afinidad de union al fcyriib.
|
EP3910331A1
(de)
|
2020-05-15 |
2021-11-17 |
iOmx Therapeutics AG |
Intrazelluläre kinase in verbindung mit resistenz gegen t-zell-vermittelte zytotoxizität und verwendungen davon
|
WO2022066595A1
(en)
|
2020-09-22 |
2022-03-31 |
Bristol-Myers Squibb Company |
Methods for producing therapeutic proteins
|
WO2022154664A1
(en)
|
2021-01-15 |
2022-07-21 |
Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis |
Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
|
WO2023015234A1
(en)
|
2021-08-05 |
2023-02-09 |
Bristol-Myers Squibb Company |
Cell culture methods for producing therapeutic proteins
|
WO2023049687A1
(en)
|
2021-09-21 |
2023-03-30 |
Bristol-Myers Squibb Company |
Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
|
EP4257132A1
(de)
|
2022-04-08 |
2023-10-11 |
iOmx Therapeutics AG |
Sik3-inhibitoren zum behandeln von krankheiten, die gegen death-rezeptor -signaltransduktion resistent sind
|